Sobi submits application for Orfadin(R) oral suspension to FDA

STOCKHOLM, Sweden, Oct. 29, 2013 (GLOBE NEWSWIRE) --

Swedish Orphan Biovitrum AB (publ) (Sobi) announced today that the company's application for Orfadin oral suspension has been submitted to the US Food and Drug Administration (FDA). This new dosage form has been developed to facilitate the ease and accuracy of administration for Orfadin in paediatric patients as well as to increase convenience for patients and their caregivers. About Orfadin Orfadin is used for the treatment of hereditary tyrosinemia type 1 (HT-1), a rare genetic disorder which can cause liver failure, kidney dysfunction and neurological problems. About Sobi Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients. The product portfolio is primarily focused on inflammation and genetic diseases, with three late stage biological development projects within haemophilia and neonatology. We also market a portfolio of specialty and rare disease products for partner companies. Sobi is a pioneer in biotechnology with world-class capabilities in protein biochemistry and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion (€ 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX Stockholm. More information is available at www.sobi.com. For more information - not for publication Media relations Investor relations Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor Communications Relations T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135 oskar.bosson@sobi.com jorgen.winroth@sobi.com Sobi submits application for Orfadin® oral suspension to FDA: http://hugin.info/134557/R/1738708/583290.pdf [HUG#1738708] Source:Swedish Orphan Biovitrum AB (publ)